Puberty blockers trial paused after MHRA raises safety concerns
BBC World
February 20, 2026
AI-Generated Deep Dive Summary
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has paused a clinical trial assessing puberty-blocking drugs in children questioning their gender due to safety concerns. The trial, led by King's College London, aimed to evaluate the impact of these medications on the physical, social, and emotional well-being of over 220 participants aged 11-15. However, the MHRA has raised concerns about the trial's current age limit (11-14) and the potential long-term biological risks associated with puberty-suppressing hormones (PSH). They have recommended increasing the minimum age to 14 and implementing stricter monitoring of bone density and consent processes.
The trial, named Pathways, was approved in November 2023 but has faced criticism from campaigners who argue that children under 18 cannot fully comprehend the risks involved. The MHRA's decision follows a review by Dr. Hilary Cass in 2024, which highlighted concerns about the safety of PSH treatments for minors. This pause reflects ongoing debates over the ethical and medical implications of puberty blockers, with some questioning their necessity and others challenging the trial's design.
The MHRA emphasized that participant safety is paramount and noted that this pause is part of the "usual process" to review clinical trials continuously. King's College London has reaffirmed its commitment to rigorous scientific discussion and prioritized the health
Verticals
worldpolitics
Originally published on BBC World on 2/20/2026